TY - JOUR
T1 - Membrane-bound SIV envelope trimers are immunogenic in ferrets after intranasal vaccination with a replication-competent canine distemper virus vector
AU - Zhang, Xinsheng
AU - Wallace, Olivia
AU - Wright, Kevin J.
AU - Backer, Martin
AU - Coleman, John W.
AU - Koehnke, Rebecca
AU - Frenk, Esther
AU - Domi, Arban
AU - Chiuchiolo, Maria J.
AU - DeStefano, Joanne
AU - Narpala, Sandeep
AU - Powell, Rebecca
AU - Morrow, Gavin
AU - Boggiano, Cesar
AU - Zamb, Timothy J.
AU - Richter King, C.
AU - Parks, Christopher L.
N1 - Funding Information:
The following reagent was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: SIV mac 251 gp120 Monoclonal Antibody (KK65 and KK17) from Dr. Karen Kent and Miss Caroline Powell. We thank Dr. Roberto Cattaneo for providing the anti-CDVFcyt rabbit serum and thank Dr. Christy Jurgens for providing the VSV-∆G-SIVenv virus and helpful suggestions. Heather Arendt, and Jennifer Martinez from IAVI provided excellent technical assistance by conducting the ferret studies. We thank Nicole Sender, Megan Finnegan, and Hanh Nguyen for proofreading the manuscript and figures. We are grateful for the helpful discussion and suggestions provided by Drs Michael Caulfield and Wayne Koff. Our thanks go to Rosanne Boyle and Beth Rasmussen, the project managers of IAVI's replicating vector program, for their excellent managerial support. This research is supported by Collaboration for AIDS Vaccine Discovery (CAVD) , which is part of The Bill and Melinda Gates Foundation, and USAID. Parts of this publication will be included in Rebecca Koehnke's dissertation. This dissertation is in progress at the time of publication of this article.
PY - 2013/11
Y1 - 2013/11
N2 - We are investigating canine distemper virus (CDV) as a vaccine vector for the delivery of HIV envelope (Env) that closely resembles the native trimeric spike. We selected CDV because it will promote vaccine delivery to lymphoid tissues, and because human exposure is infrequent, reducing potential effects of pre-existing immunity. Using SIV Env as a model, we tested a number of vector and gene insert designs. Vectors containing a gene inserted between the CDV H and L genes, which encoded Env lacking most of its cytoplasmic tail, propagated efficiently in Vero cells, expressed the immunogen on the cell surface, and incorporated the SIV glycoprotein into progeny virus particles. When ferrets were vaccinated intranasally, there were no signs of distress, vector replication was observed in the gut-associated lymphoid tissues, and the animals produced anti-SIV Env antibodies. These data show that live CDV-SIV Env vectors can safely induce anti-Env immune responses following intranasal vaccination.
AB - We are investigating canine distemper virus (CDV) as a vaccine vector for the delivery of HIV envelope (Env) that closely resembles the native trimeric spike. We selected CDV because it will promote vaccine delivery to lymphoid tissues, and because human exposure is infrequent, reducing potential effects of pre-existing immunity. Using SIV Env as a model, we tested a number of vector and gene insert designs. Vectors containing a gene inserted between the CDV H and L genes, which encoded Env lacking most of its cytoplasmic tail, propagated efficiently in Vero cells, expressed the immunogen on the cell surface, and incorporated the SIV glycoprotein into progeny virus particles. When ferrets were vaccinated intranasally, there were no signs of distress, vector replication was observed in the gut-associated lymphoid tissues, and the animals produced anti-SIV Env antibodies. These data show that live CDV-SIV Env vectors can safely induce anti-Env immune responses following intranasal vaccination.
KW - Canine distemper virus
KW - Envelope
KW - Ferret
KW - Human immunodeficiency virus
KW - Immunogen
KW - Replicating viral vector
KW - Simian immunodeficiency virus
UR - http://www.scopus.com/inward/record.url?scp=84884545338&partnerID=8YFLogxK
U2 - 10.1016/j.virol.2013.07.012
DO - 10.1016/j.virol.2013.07.012
M3 - Article
C2 - 24074564
AN - SCOPUS:84884545338
SN - 0042-6822
VL - 446
SP - 25
EP - 36
JO - Virology
JF - Virology
IS - 1-2
ER -